Inspiration Healthcare Group (IHC) H2 2025 earnings summary

Executive summary

• Revenue grew 2% to £38.2m for FY25, with a strong H2 performance (£21.2m) compared to H1 (£17m), driven by major export contracts and new product launches.

• Organizational changes included new leadership, cost-saving measures delivering annualized savings of GBP 1.2m–£1.25m, and operational restructuring.

• Product innovation included a new infusion pump series, driving 29% growth in infusion therapy and 81% growth in Airon/Aeron sales, both exceeding budget.

• Acquisition of Airon Corporation completed, contributing above-plan results in its first year.

• H2 saw a turnaround from negative EBITDA in H1 to profitability, attributed to Back-to-Basics initiatives.

Financial highlights

• Gross margin declined to 42.8% from 47.5% year-over-year, mainly due to product mix and inventory provisions.

• Adjusted EBITDA fell to £0.2m from £2.0m; statutory operating loss widened to £14.7m, including £10.3m non-cash impairment charges.

• Net debt increased to £8.3m from £6.0m, expected to reduce as large contracts are delivered and working capital unwinds.

• Infusion sales rose 29%, Airon/Aeron sales up 81%, while neonatal sales declined 15% year-over-year.

• Non-recurring items included a £10.3m goodwill impairment, £0.8m Airon contingent consideration, and £1.6m restructuring costs.

Outlook and guidance

• Strong H1 expected in FY26, supported by delivery of large Middle East and humanitarian contracts.

• Focus on margin improvement through product and geographic mix, recurring revenue growth, and operational efficiency.

• Positive outlook for FY26 with confidence in meeting market expectations and further deleveraging.

• Midterm strategy includes U.S. market entry, new consumables launch, and continued Back-to-Basics execution.